Long-term efficacy and safety outcomes with OROS-MPH in adults with ADHD

International Journal of Neuropsychopharmacology

Volumn 15, Issue 1, 2012, Pages 1-13

  Buitelaar, Jan K ^a   Trott, Götz Erik ^b   Hofecker, Maria ^c   Waechter, Sandra ^d   Berwaerts, Joris ^e   Dejonkheere, Joachim ^f   Schäuble, Barbara ^g  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Child and Adolescent Psychiatry   (Germany)

^c Private Practice   (Switzerland)

^d Janssen Cilag Europe ^*  (Switzerland)

^e JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^f SGS Medisearch International NV   (Belgium)

^g JANSSEN CILAG GMBH   (Germany)

Author keywords

Adults; attention deficit hyperactivity disorder; long term treatment; OROS MPH

Indexed keywords

METHYLPHENIDATE; CENTRAL STIMULANT AGENT; DELAYED RELEASE FORMULATION;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; BACKACHE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; HEADACHE; HUMAN; HYPERTENSION; INFLUENZA; INSOMNIA; IRRITABILITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; RHINOPHARYNGITIS; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PSYCHOLOGICAL RATING SCALE; TIME; WITHDRAWAL SYNDROME; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHYLPHENIDATE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; QUESTIONNAIRES; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84856499472     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145711001131     Document Type: Article

References (26)

1. Adler LA, Orman C, Starr HL, Silber S, et al. (2011). Long-term safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder : an open-label, dose-titration, 1-year study. Journal of Clinical Psychopharmacology 31, 108-114.
2. Adler LA, Spencer TJ, Milton DR, Moore RJ, et al. (2005). Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder : an interim analysis. Journal of Clinical Psychiatry 66, 294-299. (Pubitemid 40476751)
3. Adler LA, Zimmerman B, Starr HL, Silber S, et al. (2009). Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder : a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. Journal of Clinical Psychopharmacology 29, 239-247.
4. Bejerot S, Rydén EM, Arlinde CM (2010). Two-year outcome of treatment with central stimulant medication in adult attention-deficit/ hyperactivity disorder : a prospective study. Journal of Clinical Psychiatry 71, 1590-1597.
5. Biederman J, Mick E, Surman C, Doyle R, et al. (2010). A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral systemmethylphenidate in adults with attention-deficit/hyperactivity disorder. Journal of Clinical Psychopharmacology 30, 549-553.
6. Bouffard R, Hechtman L, Minde K, Iaboni-Kassab F (2003). The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Canadian Journal of Psychiatry 48, 546-554. (Pubitemid 37280044)
7. Buitelaar JK, Michelson D, Danckaerts M, Gillberg C, et al. (2007). A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year. Biological Psychiatry 61, 694-699. (Pubitemid 46328852)
8. Buitelaar JK, Ramos-Quiroga JA, Casas M, Kooij JJ, et al. (2009). Safety and tolerability of flexible dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Neuropsychiatric Disease and Treatment 5, 457-466.
9. Conners C, Erhardt D, Sparrow E (1999). Conners' Adult ADHD Rating Scales (CAARS) : Technical Manual. North Tonawanda, NY: Multi-Health Systems.
10. Endicott J, Nee J, Harrison W, Blumenthal R (1993). Quality of life enjoyment and satisfaction questionnaire : a new measure. Psychopharmacology Bulletin 29, 321-326. (Pubitemid 23311543)
11. Faraone SV, Biederman J, Mick E (2006). The age-dependent decline of attention deficit hyperactivity disorder : a metaanalysis of follow-up studies. Psychological Medicine 36, 159-165. (Pubitemid 43126140)
12. Johnson M, Cederlund M, Rastam M, Areskoug B, et al. (2010). Open-label trial of atomoxetine hydrochloride in adults with ADHD. Journal of Attention Disorders 13, 539-545.
13. Kooij JJ, Burger H, Boonstra AM, Van der Linden PD, et al. (2004). Efficacy and safety of methylphenidate in 45 adults with attention-deficit/ hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine 34, 973-982.
14. Kooij SJ, Bejerot S, Blackwell A, Caci H, et al. (2010). European consensus statement on diagnosis and treatment of adult ADHD: the European network adult ADHD. BMC Psychiatry 10, 67.
15. Maguire MJ, Hemming K, Hutton JL, Marson AG (2008). Reporting and analysis of open-label extension studies of anti-epileptic drugs. Epilepsy Research 81, 24-29.
16. Medori R, Ramos-Quiroga JA, Casas M, Kooij JJS, et al. (2008). A randomized, placebo-controlled trial of 3 fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biological Psychiatry 63, 981-989.
17. Michelson D, Buitelaar JK, Danckaerts M, Gillberg C, et al. (2004). Relapse prevention in pediatric patients with ADHD treated with atomoxetine : a randomized, double-blind, placebo-controlled study. Journal of the American Academy of Child and Adolescent Psychiatry 43, 896-904. (Pubitemid 38808495)
18. Mick E, Faraone SV, Spencer T, Zhang HF, et al. (2008). Assessing the validity of the quality of life enjoyment and satisfaction questionnaire short form in adults with ADHD. Journal of Attention Disorders 11, 504-509.
19. National Collaborating Centre for Mental Health (2009). Attention Deficit Hyperactivity Disorder : Diagnosis and Management of ADHD in Children, Young People and Adults. London: National Institute for Health and Clinical Excellence.
20. National Institute of Mental Health (NIMH) (1985). CGI (Clinical Global Impression Scale). Psychopharmacology Bulletin 21, 843.
21. Rösler M, Ginsberg Y, Arngrim T, Adamou M, et al. (2011). Correlation of symptomatic improvements with functional improvements and patient-reported outcomes in adults with attention-deficit/hyperactivity disorder treated with OROS methylphenidate. World Journal of Biological Psychiatry. Published online : 26 April 2011. doi :10.3109/15622975.2011.571283.
22. Sheehan DV, Harnett-Sheehan K, Raj BA (1996). The measurement of disability. International Clinical Psychopharmacology 11 (Suppl. 3), 89-95. (Pubitemid 26373761)
23. Social and Health Directory (2010). Diagnosis and Treatment of Hyperkinetic Disorder/Attention Deficit Hyperactivity Disorder (ADHD) in Children, Adolescents and Adults [in Norwegian]. Oslo: Sosial-og helsedirektoratet.
24. Spencer T, Biederman J, Wilens T, Doyle R, et al. (2005). A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry 57, 456-463. (Pubitemid 40311979)
25. Weisler R, Young J, Mattingly G, Gao J, et al. (2009). Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. CNS Spectrums 14, 573-585.
26. Wender PH, Reimherr FW, Marchant BK, Sanford ME, et al. (2011). A one year trial of methylphenidate in the treatment of ADHD. Journal of Attention Disorders 15, 36-45.